

Fig. S1. Treatment and assessment schedule. Critical stimulation time threshold (CsTT) and critical temperature threshold (CTT) were assessed before and after one year of treatment with rupatadine, 20 mg/day.




Fig. S2. (A) Critical stimulation time threshold (CsTT) and (B) critical temperature threshold (CTT) measurements case by case pre- and post-treatment with rupatadine, 20 mg/day. An improvement after one year of treatment with rupatadine was observed in patients with acquired cold urticaria. The discontinuous grey line represents the maximum stimulation time used (5 min) and lowest temperature used for stimulation (4°C).

Table SI. Demographic characteristics and clinical assessment of patients with acquired cold urticaria

Patient (sex/age, years)	Disease duration, years	Critical stimulation time threshold (s)			Critical temperature threshold (°C)			
		Pre-	Post-	Elongation n (%)	Pre-	Post-	Reduction n (%)	Evolution
1 (F/48)	1	90	180	90 (50)	14	10	4 (29)	Active
2 (F/38)	12	210	>300	91 (30)	8	<4	5 (63)	Cure
3 (F/37)	2.5	150	>300	151 (50)	14	6	7 (57)	Active
4 (F/55)	22	210	>300	91 (30)	12	<4	9 (75)	Cure
5 (F/52)	2.5	150	>300	151 (50)	18	<4	15 (83)	Cure
6 (M/51)	8.5	210	>300	91 (30)	4	<4	1 (25)	Cure
7 (M/43)	3.5	150	>300	151 (50)	16	<4	13 (81)	Cure
8 (M/40)	2	<60	240	181 (60)	24	4	20 (83)	Active
9 (M/52)	1	60	180	120 (66)	20	14	6 (30)	Active
10 (F/36)	5	180	>300	121 (40)	12	<4	9 (75)	Cure
11 (M/62)	1.5	60	>300	241 (80)	10	<4	7 (70)	Cure
12 (F/40)	2	300	>300	1 (0)	4	<4	1 (25)	Cure
13 (M/53)	3	180	210	30 (14)	14	10	4 (29)	Active
14 (M/40)	10	210	>300	81 (27)	20	<4	17 (85)	Cure
15 (F/34)	2	60	60	0 (0)	26	24	2 (7)	Active
16 (F/28)	8	120	>300	181 (60)	10	<4	7 (70)	Cure
17 (M/40)	1.5	180	>300	121 (40)	12	<4	9 (75)	Cure
18 (F/61)	5	240	>300	61 (20)	8	<4	7 (62)	Cure
19 (M/45)	3	120	>300	181 (60)	14	<4	11 (78)	Cure

n = difference between pre and post (% of post-values).